An assessment of nucleic acid amplification testing for active mycobacterial infection

Yüklə 3,88 Mb. səhifə 110/143 tarix 04.01.2022 ölçüsü 3,88 Mb. #60347

Bu səhifədəki naviqasiya:

• Financial implications

Outcomes	1.395	1.396
0.00002
ICER	-	-	$30,009,858

AFB = acid-fast bacilli; ICER = incremental cost-effectiveness ratio; NAAT = nucleic acid amplification test

Financial implications

A market-based approach is taken using MBS data to estimate the number of patients who accessed at least one of item of mycobacterial MC&S testing in 200913, and to project the expected number of patients who would be eligible for NAAT for TB and NTM (as requested) in 201519. One NAAT is assumed per eligible patient. As NAAT is not intended to replace current testing, the estimated net financial implication to the MBS is equal to the cost of the requested NAAT listings multiplied by the expected number of services.

Yüklə 3,88 Mb.

Dostları ilə paylaş: